Treating Comorbidities
1 POTS Management
2 Mast Cell Activation Syndrome
For the subset of ME/CFS patients with comorbid MCAS (estimated 17–25% (Rohrhofer et al. 2025); see Section Circadian Mast Cell Regulation and Potential Temporal Learning for mechanistic discussion), dietary intervention represents a first-line therapeutic approach with low energy cost and minimal pharmacological processing burden (Category A–B). The challenge lies in identifying individual food triggers when standard allergy testing is negative.
2.1 Pharmacological Mast Cell Management
Mast cell-directed pharmacotherapy in ME/CFS follows a stepwise approach, starting with the lowest-energy-cost interventions. H1 antihistamines (cetirizine, loratadine; Category B) and H2 antihistamines (famotidine; Category B) are first-line, blocking two of the primary mediator pathways with minimal metabolic processing demands. Second-line agents include mast cell stabilizers (cromolyn sodium, ketotifen; Category B), which reduce degranulation frequency rather than blocking mediator effects. Weinstock et al. (Weinstock, Nelson, and Blitshteyn 2023) documented resolution of neuropsychiatric symptoms in all eight MCAS patients treated with this combination approach, though the case series design limits generalizability. For patients with prominent prostaglandin-mediated symptoms (flushing, abdominal cramping, diarrhea), aspirin or other COX inhibitors may be considered, but these carry higher energy cost (Category C) and gastrointestinal risk.
In POTS patients with mast cell activation, Kohno et al. (Kohno et al. 2021) found tryptase elevated in only 9%, while histamine/methylhistamine was elevated in 52% and prostaglandin D2 in 36%. Relying on tryptase alone for MCAS screening will miss the majority of food-triggered mast cell activation cases. Urinary mediator panels (N-methylhistamine, leukotriene E4, prostaglandin D2 metabolite) offer superior sensitivity and can be collected at home (Voelker and Pongdee 2024) (Voelker and Pongdee 2025).
2.2 Dietary Approaches for Mast Cell Stabilization
Low-histamine diet. The most widely recommended dietary intervention for MCAS targets exogenous histamine load. Histamine accumulates in aged, fermented, and preserved foods (aged cheese, cured meats, sauerkraut, wine, vinegar, canned fish). A low-histamine elimination diet for a minimum of four weeks, followed by systematic reintroduction, is the primary diagnostic-therapeutic tool (Comas-Basté et al. 2020). Patient survey data indicate approximately 51% of MCAS patients report improvement on low-histamine diets, 19% report no benefit, and 30% are uncertain. No randomized controlled trial has validated this protocol specifically in MCAS or ME/CFS.
Histamine intolerance—impaired histamine degradation due to diamine oxidase (DAO) deficiency rather than excess production—may coexist with or mimic MCAS. Over 50 single-nucleotide polymorphisms in the DAO-encoding gene (AOC1) have been identified, and 10 of 13 studies showed greater than 50% symptom improvement with low-histamine diets (Comas-Basté et al. 2020). DAO supplementation before meals is a low-risk adjunct (Category A), though evidence remains limited to five small intervention studies.
Dietary fiber and SCFA production. Short-chain fatty acids produced from dietary fiber fermentation by gut microbiota—particularly butyrate and propionate—inhibit mast cell degranulation via JNK suppression and HDAC inhibition (Folkerts et al. 2018). Fiber polysaccharides also directly inhibit degranulation independently of fermentation. This suggests that low-fiber diets, common in ME/CFS patients who self-restrict due to gastrointestinal sensitivity, may paradoxically increase mast cell reactivity. Gradual fiber reintroduction (starting with soluble fiber sources: oats, psyllium, cooked vegetables) may help restore endogenous mast cell inhibition, though this mechanism has not been tested clinically in MCAS or ME/CFS populations.
Food additive avoidance. Sodium sulfite (wine, dried fruit, processed foods) triggers mast cell activation through oxidative pathways independent of IgE (Pepper, Sriaroon, and Glaum 2020). Natural colorants (carmine, annatto) have stronger evidence for genuine hypersensitivity than synthetic dyes. A practical approach for energy-limited patients is to prioritize whole, unprocessed foods—which simultaneously reduces additive exposure, histamine content (when fresh), and lectin load—rather than attempting to identify and avoid specific additives individually.
3 POTS Management
4 Mast Cell Activation Syndrome
In POTS patients with mast cell activation, Kohno et al. (Kohno et al. 2021) found tryptase elevated in only 9%, while histamine/methylhistamine was elevated in 52% and prostaglandin D2 in 36%. Relying on tryptase alone for MCAS screening will miss the majority of food-triggered mast cell activation cases. Urinary mediator panels (N-methylhistamine, leukotriene E4, prostaglandin D2 metabolite) offer superior sensitivity and can be collected at home (Voelker and Pongdee 2024) (Voelker and Pongdee 2025).
Section label: @sec-low-histamine-butyrate-protocol
Mechanism and Rationale.
MCAS patients often experience histamine intolerance that complicates butyrate supplementation, which may be formulated with histamine-containing excipients (yeast-based flavorings, fermented preservatives, aged cheese extracts). Low-histamine butyrate protocols combine butyrate supplementation with dietary histamine management and mast cell stabilizers to improve tolerability in histamine-sensitive MCAS-ME/CFS patients.
Practical Implementation.
Butyrate Formulation Selection:
- Histamine-free butyrate source: Look for sodium butyrate or calcium magnesium butyrate with non-fermented, fresh excipients. Avoid yeast-based flavorings, aged preservatives, or histamine-rich formulations.
- Liquid formulations: Preferred for butyrate; look for drug manufacturer specifications on histamine content.
- Dosage: Start with 250 mg/day sodium butyrate equivalent; titrate to 500–750 mg/day based on tolerability.
Dietary Histamine Management:
- Low-histamine diet: Eliminate aged, fermented, and preserved foods (aged cheese, cured meats, sauerkraut, wine, vinegar, canned fish) for 4 weeks minimum.
- Fresh foods: Prioritize fresh proteins, cooked vegetables, and fruits (avoid high-histamine fruits: tomato, spinach, strawberries).
- Histamine degradation: DAO supplementation (100–200 mg before meals) may help if DAO deficiency suspected.
- Avoid histamine potentiators: Limit alcohol (direct DAO inhibitor), processed foods (preservatives increase histamine content), and histamine-releasing foods (citrus, fermented dairy).
Mast Cell Stabilizer Combination:
- Cromolyn sodium: 200–400 mg four times daily (oral) — mast cell stabilizer that reduces degranulation frequency.
- Ketotifen: 1 mg twice daily (if cromolyn insufficient) — mast cell stabilizer with stronger effect.
- Low-dose quercetin: 500 mg twice daily (mast cell stabilizer; caution: high-dose quercetin may have pro-inflammatory effects in some patients).
- PEA: 300–600 mg twice daily (endocannabinoid modulator; anti-inflammatory; low interaction risk with butyrate).
Expected Benefits:
- Improved butyrate tolerability in histamine-sensitive MCAS patients (reduced histamine-mediated side effects: flushing, headaches, GI upset).
- Enhanced gut barrier integrity (butyrate) combined with reduced mast cell degranulation (cromolyn, ketotifen, low-histamine diet).
- Reduced systemic inflammation (butyrate via HDAC inhibition, mast cell stabilizers via reduced mediator release).
- Reduced histamine-mediated symptoms (flushing, itching, GI upset) during butyrate supplementation.
Evidence and Certainty.
Certainty: 0.50. Mechanistically grounded in histamine intolerance physiology, butyrate’s safety profile, and mast cell stabilizer mechanisms (well-established). Direct clinical evidence for low-histamine butyrate protocols in ME/CFS-MCAS patients is lacking; the proposed protocol extends from component mechanisms (histamine-free butyrate, low-histamine diet, mast cell stabilizers) to a combined approach. The intervention is low-risk, low-cost, and addresses specific tolerability challenges faced by MCAS patients.
Testable Predictions.
- MCAS patients using low-histamine butyrate protocols will show improved tolerability (reduced histamine-mediated side effects) compared to high-histamine butyrate formulations.
- Combined butyrate + mast cell stabilizer + low-histamine diet will show additive improvement in gut barrier markers (zonulin, LPS, I-FABP) compared to butyrate alone.
- Low-histamine butyrate protocol will reduce histamine-mediated symptoms (flushing, itching, GI upset) during supplementation compared to high-histamine butyrate.
Limitations.
- No randomized controlled trials exist for low-histamine butyrate protocols in ME/CFS-MCAS patients.
- Histamine-free butyrate formulations may be less widely available than standard formulations.
- Individual variability in histamine intolerance severity is likely; some patients may tolerate standard butyrate formulations.
- Low-histamine diet requires significant dietary restriction; may be challenging to maintain long-term.
- Mast cell stabilizers (cromolyn, ketotifen) may have GI side effects (diarrhea, nausea) at higher doses, potentially complicating butyrate-tolerability assessment.
- Long-term safety of combined butyrate + mast cell stabilizer protocols is untested.
Clinical Recommendation.
Consider low-histamine butyrate protocols for MCAS-ME/CFS patients experiencing histamine-mediated side effects with standard butyrate formulations. The protocol combines histamine-free butyrate supplementation, low-histamine diet, and mast cell stabilizers to improve tolerability and enhance gut barrier support. Requires medical supervision to optimize dosing and monitor for interactions.
(Section label: @sec-low-histamine-butyrate-protocol)
Certainty: 0.50. Mechanistically grounded; direct ME/CFS evidence lacking; protocol addresses specific tolerability challenges faced by MCAS patients.
Section label: @sec-wheat-butyrate-interaction-protocol
Mechanism and Rationale.
The wheat-primed exercise intolerance hypothesis (Additional Integrative Topics) proposes that wheat exposure creates a vulnerable intestinal barrier (gliadin-mediated permeability + ATI inflammation), which exacerbates exercise-induced ischemia, endotoxemia, and PEM. This protocol tests the hypothesis that butyrate supplementation during wheat rechallenge can mitigate barrier failure by supporting tight junctions and reducing inflammation.
Practical Implementation.
Phase 1: Baseline Assessment (Weeks 1–2)
- Measure baseline PEM severity (0–10 scale), daily step count, GI symptoms (bloating, cramping, diarrhea)
- Collect stool samples for baseline butyrate levels (target: \(<\) 20 \(\mu\)mol/L, typical of ME/CFS)
- Measure gut barrier markers: zonulin (serum), LPS (serum), I-FABP (serum)
- Establish daily activity baseline (steps, hours upright)
Phase 2: Wheat Elimination (Weeks 3–6)
- Strict wheat elimination (no gluten-containing foods)
- Maintain butyrate supplementation (target 500–750 mg/day sodium butyrate or equivalent)
- Monitor PEM severity, steps, GI symptoms weekly
- Expected: baseline improvement in PEM severity and GI symptoms in wheat-sensitive responders
Phase 3: Wheat Rechallenge + Butyrate Supplementation (Weeks 7–9)
- Reintroduce wheat (2 slices bread/day or equivalent)
- Continue butyrate supplementation throughout rechallenge
- Monitor PEM severity, steps, GI symptoms 24–72 hours post-rechallenge
- Compare to baseline (pre-elimination) and post-elimination levels
Phase 4: Analysis and Decision (Week 10)
- If PEM severity worsens by \(\ge\) 2 points on 0–10 scale within 24–72 hours of wheat rechallenge: wheat-sensitive confirmed
- If no change or improvement: wheat sensitivity not primary mechanism
- If improvement continues without worsening: consider gluten/FODMAP-specific factors (requires pure gluten or pure FODMAP challenge)
Expected Outcomes in Wheat-Butyrate Interaction Responders.
- Wheat elimination produces 20–50% PEM reduction and GI symptom improvement
- Wheat rechallenge triggers PEM exacerbation within 24–72 hours
- Butyrate supplementation during rechallenge partially mitigates PEM severity (estimated 30–60% reduction in PEM exacerbation vs. rechallenge without butyrate)
- Gut barrier markers (zonulin, LPS, I-FABP) show improvement during elimination, partial worsening during rechallenge
Evidence and Certainty.
Certainty: 0.55. Mechanistically grounded in wheat-induced barrier dysfunction, butyrate’s tight junction support, and the wheat-primed exercise intolerance hypothesis (well-established). Direct clinical evidence for the butyrate-wheat interaction in ME/CFS is lacking; the proposed protocol extends from component mechanisms to a specific testing framework. The intervention is low-risk, low-cost, and provides a clear decision tree for wheat sensitivity testing.
Testable Predictions.
- Responders to wheat elimination will show measurable improvement in baseline PEM severity and GI symptoms.
- Wheat rechallenge will trigger PEM exacerbation in responders (within 24–72 hours).
- Butyrate supplementation during wheat rechallenge will reduce PEM exacerbation severity compared to rechallenge without butyrate (measured via PEM severity scale, steps, gut barrier markers).
- Gut barrier markers (zonulin, LPS, I-FABP) will show improvement during wheat elimination and partial worsening during rechallenge, with butyrate attenuating the rechallenge worsening.
Limitations.
- No randomized controlled trials exist for this specific wheat-butyrater interaction protocol.
- Requires 10-week protocol; adherence challenges in severely fatigued patients.
- Placebo/nocebo effects are significant in dietary interventions; objective measures (steps, biomarkers) essential.
- Fructan/FODMAP confounding may obscure gluten-specific effects; requires careful dietary control or pure gluten challenge if gluten sensitivity suspected.
- Individual variability in wheat sensitivity prevalence (estimated 15% of ME/CFS cohorts) limits generalizability.
Clinical Recommendation.
Consider this protocol for patients reporting wheat-exacerbated PEM and GI symptoms, particularly those interested in testing the butyrate-wheat interaction hypothesis. The protocol provides a clear decision tree for wheat sensitivity testing while optimizing gut barrier function through butyrate supplementation.
(Section label: @sec-wheat-butyrate-interaction-protocol)
Certainty: 0.55. Mechanistically grounded; direct ME/CFS evidence lacking; protocol is low-risk, well-structured, and provides clear decision criteria for wheat sensitivity testing.
No randomized controlled trial has tested dietary elimination in ME/CFS patients with confirmed MCAS as a comorbidity. The evidence supporting this approach comes from MCAS clinical practice guidelines, patient survey data showing \(\sim\) 51% response rates, and the mechanistic rationale that reducing mast cell activation burden should reduce mediator-driven symptom load. Individual dietary response varies substantially, and the protocol itself carries an energy cost (cognitive effort, meal planning, social restriction) that must be weighed against potential benefit. Patients who do not improve after 6 weeks of strict elimination should discontinue the protocol rather than pursuing increasingly restrictive diets.
4.1 Pharmacological Mast Cell Management
4.2 Dietary Approaches for Mast Cell Stabilization
4.3 Elimination-Rechallenge Protocol for Energy-Limited Patients
5 Ehlers-Danlos Syndrome
6 Other Common Comorbidities
6.1 Sleep Apnea Misdiagnosis
6.2 Lyme Disease (European Species)
6.3 Ehlers-Danlos Syndrome and Mast Cell Activation
In POTS patients with mast cell activation, Kohno et al. (Kohno et al. 2021) found tryptase elevated in only 9%, while histamine/methylhistamine was elevated in 52% and prostaglandin D2 in 36%. Relying on tryptase alone for MCAS screening will miss the majority of food-triggered mast cell activation cases. Urinary mediator panels (N-methylhistamine, leukotriene E4, prostaglandin D2 metabolite) offer superior sensitivity and can be collected at home (Voelker and Pongdee 2024) (Voelker and Pongdee 2025).
Section label: @sec-low-histamine-butyrate-protocol
Mechanism and Rationale.
MCAS patients often experience histamine intolerance that complicates butyrate supplementation, which may be formulated with histamine-containing excipients (yeast-based flavorings, fermented preservatives, aged cheese extracts). Low-histamine butyrate protocols combine butyrate supplementation with dietary histamine management and mast cell stabilizers to improve tolerability in histamine-sensitive MCAS-ME/CFS patients.
Practical Implementation.
Butyrate Formulation Selection:
- Histamine-free butyrate source: Look for sodium butyrate or calcium magnesium butyrate with non-fermented, fresh excipients. Avoid yeast-based flavorings, aged preservatives, or histamine-rich formulations.
- Liquid formulations: Preferred for butyrate; look for drug manufacturer specifications on histamine content.
- Dosage: Start with 250 mg/day sodium butyrate equivalent; titrate to 500–750 mg/day based on tolerability.
Dietary Histamine Management:
- Low-histamine diet: Eliminate aged, fermented, and preserved foods (aged cheese, cured meats, sauerkraut, wine, vinegar, canned fish) for 4 weeks minimum.
- Fresh foods: Prioritize fresh proteins, cooked vegetables, and fruits (avoid high-histamine fruits: tomato, spinach, strawberries).
- Histamine degradation: DAO supplementation (100–200 mg before meals) may help if DAO deficiency suspected.
- Avoid histamine potentiators: Limit alcohol (direct DAO inhibitor), processed foods (preservatives increase histamine content), and histamine-releasing foods (citrus, fermented dairy).
Mast Cell Stabilizer Combination:
- Cromolyn sodium: 200–400 mg four times daily (oral) — mast cell stabilizer that reduces degranulation frequency.
- Ketotifen: 1 mg twice daily (if cromolyn insufficient) — mast cell stabilizer with stronger effect.
- Low-dose quercetin: 500 mg twice daily (mast cell stabilizer; caution: high-dose quercetin may have pro-inflammatory effects in some patients).
- PEA: 300–600 mg twice daily (endocannabinoid modulator; anti-inflammatory; low interaction risk with butyrate).
Expected Benefits:
- Improved butyrate tolerability in histamine-sensitive MCAS patients (reduced histamine-mediated side effects: flushing, headaches, GI upset).
- Enhanced gut barrier integrity (butyrate) combined with reduced mast cell degranulation (cromolyn, ketotifen, low-histamine diet).
- Reduced systemic inflammation (butyrate via HDAC inhibition, mast cell stabilizers via reduced mediator release).
- Reduced histamine-mediated symptoms (flushing, itching, GI upset) during butyrate supplementation.
Evidence and Certainty.
Certainty: 0.50. Mechanistically grounded in histamine intolerance physiology, butyrate’s safety profile, and mast cell stabilizer mechanisms (well-established). Direct clinical evidence for low-histamine butyrate protocols in ME/CFS-MCAS patients is lacking; the proposed protocol extends from component mechanisms (histamine-free butyrate, low-histamine diet, mast cell stabilizers) to a combined approach. The intervention is low-risk, low-cost, and addresses specific tolerability challenges faced by MCAS patients.
Testable Predictions.
- MCAS patients using low-histamine butyrate protocols will show improved tolerability (reduced histamine-mediated side effects) compared to high-histamine butyrate formulations.
- Combined butyrate + mast cell stabilizer + low-histamine diet will show additive improvement in gut barrier markers (zonulin, LPS, I-FABP) compared to butyrate alone.
- Low-histamine butyrate protocol will reduce histamine-mediated symptoms (flushing, itching, GI upset) during supplementation compared to high-histamine butyrate.
Limitations.
- No randomized controlled trials exist for low-histamine butyrate protocols in ME/CFS-MCAS patients.
- Histamine-free butyrate formulations may be less widely available than standard formulations.
- Individual variability in histamine intolerance severity is likely; some patients may tolerate standard butyrate formulations.
- Low-histamine diet requires significant dietary restriction; may be challenging to maintain long-term.
- Mast cell stabilizers (cromolyn, ketotifen) may have GI side effects (diarrhea, nausea) at higher doses, potentially complicating butyrate-tolerability assessment.
- Long-term safety of combined butyrate + mast cell stabilizer protocols is untested.
Clinical Recommendation.
Consider low-histamine butyrate protocols for MCAS-ME/CFS patients experiencing histamine-mediated side effects with standard butyrate formulations. The protocol combines histamine-free butyrate supplementation, low-histamine diet, and mast cell stabilizers to improve tolerability and enhance gut barrier support. Requires medical supervision to optimize dosing and monitor for interactions.
(Section label: @sec-low-histamine-butyrate-protocol)
Certainty: 0.50. Mechanistically grounded; direct ME/CFS evidence lacking; protocol addresses specific tolerability challenges faced by MCAS patients.
Section label: @sec-wheat-butyrate-interaction-protocol
Mechanism and Rationale.
The wheat-primed exercise intolerance hypothesis (Additional Integrative Topics) proposes that wheat exposure creates a vulnerable intestinal barrier (gliadin-mediated permeability + ATI inflammation), which exacerbates exercise-induced ischemia, endotoxemia, and PEM. This protocol tests the hypothesis that butyrate supplementation during wheat rechallenge can mitigate barrier failure by supporting tight junctions and reducing inflammation.
Practical Implementation.
Phase 1: Baseline Assessment (Weeks 1–2)
- Measure baseline PEM severity (0–10 scale), daily step count, GI symptoms (bloating, cramping, diarrhea)
- Collect stool samples for baseline butyrate levels (target: \(<\) 20 \(\mu\)mol/L, typical of ME/CFS)
- Measure gut barrier markers: zonulin (serum), LPS (serum), I-FABP (serum)
- Establish daily activity baseline (steps, hours upright)
Phase 2: Wheat Elimination (Weeks 3–6)
- Strict wheat elimination (no gluten-containing foods)
- Maintain butyrate supplementation (target 500–750 mg/day sodium butyrate or equivalent)
- Monitor PEM severity, steps, GI symptoms weekly
- Expected: baseline improvement in PEM severity and GI symptoms in wheat-sensitive responders
Phase 3: Wheat Rechallenge + Butyrate Supplementation (Weeks 7–9)
- Reintroduce wheat (2 slices bread/day or equivalent)
- Continue butyrate supplementation throughout rechallenge
- Monitor PEM severity, steps, GI symptoms 24–72 hours post-rechallenge
- Compare to baseline (pre-elimination) and post-elimination levels
Phase 4: Analysis and Decision (Week 10)
- If PEM severity worsens by \(\ge\) 2 points on 0–10 scale within 24–72 hours of wheat rechallenge: wheat-sensitive confirmed
- If no change or improvement: wheat sensitivity not primary mechanism
- If improvement continues without worsening: consider gluten/FODMAP-specific factors (requires pure gluten or pure FODMAP challenge)
Expected Outcomes in Wheat-Butyrate Interaction Responders.
- Wheat elimination produces 20–50% PEM reduction and GI symptom improvement
- Wheat rechallenge triggers PEM exacerbation within 24–72 hours
- Butyrate supplementation during rechallenge partially mitigates PEM severity (estimated 30–60% reduction in PEM exacerbation vs. rechallenge without butyrate)
- Gut barrier markers (zonulin, LPS, I-FABP) show improvement during elimination, partial worsening during rechallenge
Evidence and Certainty.
Certainty: 0.55. Mechanistically grounded in wheat-induced barrier dysfunction, butyrate’s tight junction support, and the wheat-primed exercise intolerance hypothesis (well-established). Direct clinical evidence for the butyrate-wheat interaction in ME/CFS is lacking; the proposed protocol extends from component mechanisms to a specific testing framework. The intervention is low-risk, low-cost, and provides a clear decision tree for wheat sensitivity testing.
Testable Predictions.
- Responders to wheat elimination will show measurable improvement in baseline PEM severity and GI symptoms.
- Wheat rechallenge will trigger PEM exacerbation in responders (within 24–72 hours).
- Butyrate supplementation during wheat rechallenge will reduce PEM exacerbation severity compared to rechallenge without butyrate (measured via PEM severity scale, steps, gut barrier markers).
- Gut barrier markers (zonulin, LPS, I-FABP) will show improvement during wheat elimination and partial worsening during rechallenge, with butyrate attenuating the rechallenge worsening.
Limitations.
- No randomized controlled trials exist for this specific wheat-butyrater interaction protocol.
- Requires 10-week protocol; adherence challenges in severely fatigued patients.
- Placebo/nocebo effects are significant in dietary interventions; objective measures (steps, biomarkers) essential.
- Fructan/FODMAP confounding may obscure gluten-specific effects; requires careful dietary control or pure gluten challenge if gluten sensitivity suspected.
- Individual variability in wheat sensitivity prevalence (estimated 15% of ME/CFS cohorts) limits generalizability.
Clinical Recommendation.
Consider this protocol for patients reporting wheat-exacerbated PEM and GI symptoms, particularly those interested in testing the butyrate-wheat interaction hypothesis. The protocol provides a clear decision tree for wheat sensitivity testing while optimizing gut barrier function through butyrate supplementation.
(Section label: @sec-wheat-butyrate-interaction-protocol)
Certainty: 0.55. Mechanistically grounded; direct ME/CFS evidence lacking; protocol is low-risk, well-structured, and provides clear decision criteria for wheat sensitivity testing.
No randomized controlled trial has tested dietary elimination in ME/CFS patients with confirmed MCAS as a comorbidity. The evidence supporting this approach comes from MCAS clinical practice guidelines, patient survey data showing \(\sim\) 51% response rates, and the mechanistic rationale that reducing mast cell activation burden should reduce mediator-driven symptom load. Individual dietary response varies substantially, and the protocol itself carries an energy cost (cognitive effort, meal planning, social restriction) that must be weighed against potential benefit. Patients who do not improve after 6 weeks of strict elimination should discontinue the protocol rather than pursuing increasingly restrictive diets.